РАЗРАБОТКА НЕИНЪЕКЦИОННЫХ ПРЕПАРАТОВ ЦЕНТРАЛЬНОГО ДЕЙСТВИЯ ДЛЯ НЕОТЛОЖНОЙ ТЕРАПИИ

На примере сильнодействующих анальгетиков обоснован алгоритм выбора соединений и лекарственных форм для разработки универсальных ЦНС-таргетных препаратов для неотложной военно-полевой и гражданской терапии. Выделены ключевые критерии и количественные параметры выбора веществ и лекарственных форм. Продемонстрированы преимущества сильнодействующих синтетических опиоидов относительно традиционно используемого морфина, его производных и аналогов. Показаны преимущества мультитаргетных препаратов. Обоснован выбор трансмукозных лекарственных форм анальгетиков, противорвотных средств и антидотов для неотложной терапии. Предложены подходы к разработке универсальной фармакологической платформы для создания ЦНС-направленных средств терапии. Описана текущая ситуация в области сильнодействующих анальгетиков и других лекарств ограниченного использования в РФ, отмечены проблемы и предложены возможные решения.

анальгетик, неотложная терапия, опиоид, коэффициент распределения, трансмукозная лекформа, мультитаргетный препарат, антидот

1. K. Modjarrad, V.S. Moorthy, P. Millett, P.S. Gsell, C. Roth, M.P. Kieny. Developing Global Norms for Sharing Data and Results during Public Health Emergencies // PLoS Med. 2016. V. 13(1). P. 1-5.

2. P. Vallance, A. Freeman, M. Stewart. Data Sharing as Part of the Normal Scientific Process: A View from the Pharmaceutical Industry // PLoS Med. 2016. V. 13(1). e1001936.

3. ‘Non-Lethal’ Weapons / Ed. By N. Davison. - 2009. 304 p.

4. Chemical Control. Regulation of Incapacitating Chemical Agent Weapons, Riot Control Agents and their Means of Delivery / Ed. by M. Crowley. - 2016. 378 p.

5. OPCW. URL: https://www.opcw.org/about-chemical-weapons/types-of-chemical-agent/nerve-agents/ (дата обращения 24.12.2017).

6. Herbicidal warfare. URL: https://en.wikipedia.org/wiki/Herbicidal_warfare (дата обращения 09.12.2017).

7. Конвенция о запрещении разработки, производства, накопления и применения химического оружия и его уничтожении. Официальный документ ООН и OPCW (ред. от 29.07.2005). URL: https://www.opcw.org/fileadmin/OPCW/CWC/CWC_ru.pdf (дата обращения 14.12.2017).

8. W.J. Zhang, F. Jiang, J.F. Ou. Global pesticide consumption and pollution: with China as a focus // Proceedings of the International Academy of Ecology and Environmental Sciences. 2011. V. 1(2). P. 125-144.

9. M. Roser, H. Ritchie. Fertilizer and Pesticides. Our World in Data. URL: https://ourworldindata.org/fertilizer-and-pesticides/#fertilizer-production (дата обращения 14.12.2017).

10. Basic and Clinical Toxicology of Organophosphorus Compounds / Ed. by M. Balali-Mood and M. Abdollahi. - London. Springer-Verlag, 2014. 257 p.

11. B. Madea, F. Mußhoff. Knock-Out Drugs: Their Prevalence, Modes of Action, and Means of Detection // Dtsch Arztebl Int. 2009. V. 106(20). P. 341-7.

12. K. Perry. New spate of attacks by sleeping gas gang, caravanners warned // The Telegraph. 01.09.2014. URL: http://www.telegraph.co.uk/news/uknews/crime/11068184/New-spate-of-attacks-by-sleeping-gas-gang-caravanners-warned.html (дата обращения 14.12.2017).

13. Brad Ringeisen. Battlefield Medicine. URL: https://www.darpa.mil/program/battlefield-medicine (дата обращения 14.12.2017).

14. J. Sanchez. Systems-Based Neurotechnology for Emerging Therapies (DARPA SUBNETS). URL: https://www.darpa.mil/program/systems-based-neurotechnology-for-emerging-therapies (дата обращения 14.12.2017).

15. A. Anighoro, J. Bajorath, G. Rastelli. Polypharmacology: Challenges and Opportunities in Drug Discovery // J. Med. Chem. 2014. V. 57 (19). P. 7874-7887.

16. K. Barnett, S.W. Mercer, M. Norbury, G. Watt. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study // The Lancet. 2012. V. 380. P. 37-43.

17. А.В. Соснов, Ф.М. Семченко, М.И. Власов, В.Н. Тохмахчи, А.А. Соснова. Развитие комплексной фармакотерапии сильной и средней боли. Ч. 1. Мультитаргетное комбинирование опиоидов и ненаркотических анальгетиков центрального действия // Разработка и регистрация лекарственных средств. 2017. №2 (19). С. 176-187.

18. S.O. Bachurin, E.F. Shevtsova, G.F. Makhaeva et al. Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment // Scientific Reports. 2017. P. 1-15. URL: http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC5372361&blobtype=pdf (дата обращения 14.12.2017).

19. An Organophosphate Poisoning Antidote Capable of Crossing the Blood-Brain Barrier. UCSD Tech ID: 22601 / UC Case 2012-317-0. URL: https://techtransfer.universityofcalifornia.edu/NCD/22601.html (дата обращения 14.12.2017).

20. Z. Radic, R.K. Sit, Z. Kovarik, S. Berend,E. Garcia, L. Zhang, G. Amitai, C. Green, B. Radic, V.V. Fokin, K.B. Sharpless, P. Taylor. Refinement of structural leads for centrally acting oxime reactivators of phosphylated cholinesterases // J Biol Chem. 2012. V. 6 287(15). P. 11798-11809.

21. Patent US 20150361060 A1. Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them / P. Taylor, Z. Radic, K. Barry. - 2015.

22. J.E. Chambers, E.C. Meek, H.W. Chambers. Novel brain-penetrating oximes for reactivation of cholinesterase inhibited by sarin and VX surrogates // Ann NY Acad Sci. 2016. V. 1374(1). P. 52-58.

23. Y.J. Rosenberg, L. Mao, X. Jiang, J. Lees, L. Zhang, Z. Radic, P. Taylor. Postexposure treatment with the oxime RS194B rapidly reverses early and advanced symptoms in macaques exposed to sarin vapor // Chem Biol Interact. 2017. V. 25(274). P. 50-57.

24. Opioid Therapy in the 21st Century. Second Edition / Ed. by H.S. Smith. - London: Oxford University Press, 2013. 306 p.

25. A. Kokate, X. Li, B. Jasti. Effect of Drug Lipophilicity and Ionization on Permeability Across the Buccal Mucosa: A Technical Note // AAPS PharmSciTech. 2008. V. 9 (2). P. 501-504.

26. A. Yassen, E. Olofsen, A. Dahan, M. Danhof. Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine and Fentanyl in Rats: Role of Receptor Equilibration Kinetics // The journal of pharmacology and experimental therapeutics. 2005. V. 313(3). P. 1136-1149.

27. J. Lotsch. Pharmacokinetic-Pharmacodynamic Modeling of Opioids // Journal of Pain and Symptom Management. 2005. V. 29 (5S). P. 90-103.

28. Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care / Ed. by A.D. Kaye and A.M. Kaye. - N.Y.: Springer, 2014. 904 p.

29. A. Andrés, M. Rosés, C. Ràfols, E. Bosch, S. Espinosa, V. Segarra, J.M. Huerta. Setup and validation of shake-flask procedures for the determination of partition coefficients (logD) from low drug amounts // Eur J Pharm Sci. 2015. V. 30(76). P. 181-191.

30. LogD Predictor. ChemAxon. URL: https://disco.chemaxon.com/apps/demos/logd/ (дата обращения 14.12.2017).

31. M. Danhof. Systems pharmacology - Towards the modeling of network interactions // European Journal of Pharmaceutical Sciences. 2016. V. 94. P. 4-14. URL: http://dx.doi.org/10.1016/ (дата обращения 10.12.2017).

32. Y. Hu, J. Bajorath. Entering the ‘big data’ era in medicinal chemistry: molecular promiscuity analysis revisited // Future Sci. OA. 2017. V. 3(2). FSO179.

33. Drug Research Advisor. Clarivate Analytics. URL: https://clarivate.com/products/drug-research-advisor/ (дата обращения 14.12.2017).

34. База данных Integrity. URL: https://clarivate.com/training/training-overview-ls/integrity/#quicktabs-live_training_tabs_integrity=2 (дата обращения 14.12.2017).

35. A. Williams, E. Baird. Special Considerations for the Treatment of Pain from Torture and War // Curr Anesthesiol Rep. 2016. V. 6. P. 319-326.

36. J. Breslow, A. Monrow, J. Daly, J. Meissier, J. Gauyhan, M. Alder, T. Eisenstein. Morphine not trauma sensitizes to systemic Acinetobacter baumannii infection // J NeuroImmune Pharmacol. 2011. V. 6(4). P. 551-65.

37. Morphine-Induced Immunosuppression, From Brain to Spleen. NIDA. URL: https://www.drugabuse.gov/news-events/nida-notes/2008/06/morphine-induced-immunosuppression-brain-to-spleen (дата обращения 14.12.2017).

38. P. Sacerdote, S. Franchi, A.E. Panerai. Non-analgesic effects of opioids: mechanisms and potential clinical relevance of opioid-induced immunodepression // Curr Pharm Des. 2012. V. 18(37). P. 6034-42.

39. S. Bimonte, A Barbieri, D. Rea et al. Morphine Promotes Tumor Angiogenesis and Increases Breast Cancer Progression // BioMed Research International. 2015. V. 2015, Article ID 161508. P. 1-8.

40. K. Gupta, S. Kshirsagar, L. Chang et al. Morphine Stimulates Angiogenesis by Activating Proangiogenic and Survivalpromoting Signaling and Promotes Breast Tumor Growth // Cancer Research. 2002. V. 62. P. 4491-4498.

41. А.В. Соснов, С.В. Садовников, Ф.М. Семченко, К.А. Руфанов, В.Н. Тохмахчи, А.А. Соснова, И.А. Тюрин. Сильнодействующие ненаркотические анальгетики как направление развития фармацевтики // Разработка и регистрация лекарственных средств. 2016. № 1(14). С. 196-206.

42. TCCC Tactical Combat Casualty Care Guidelines URL: https://www.itstactical.com/medcom/tccc-medcom/2014-tccc-tactical-combat-casualty-care-guidelines/ (дата обращения 14.12.2017).

43. F.K. Butler, R.S. Kotwal, C.C. Buckenmaier. A Triple-Option Analgesia Plan for Tactical Combat Casualty Care: TCCC Guidelines Change 13-04 // Journal of special operations medicine: a peer reviewed journal for SOF medical professionals. 2014. V. 14 (1). P. 13-25.

44. A.D. Fisher, B. Rippee, H. Shehan, C. Conklin, R.L. Mabry. Prehospital analgesia with ketamine for combat wounds: a case series // J Spec Oper Med. 2014. V. 14(4). P. 11-17.

45. A. Eremenko, L. Sorokina. Nefopam, ketoprofen and trimeperidine in analgesia // Annu Meet Eur Soc Anaesthesiol. 2014. Abst 14AP8-6.

46. M.A. Yudin, N.G. Vengerovich, G.S. Sagalov, M.S. Vahvijanen, V.N. Bykov, S.V. Chepur. Changes in Respiratory Function during Treatment with Combination of Analgesic Substances Trimeperidine and Dexmedetomidine // Bulletin of Experimental Biology and Medicine. 2016. V. 162 (2). P. 215-219.

47. M.S. Cepeda, D.B. Carr. Comparison of Morphine, Ketorolac, and Their Combination for Postoperative Pain. Results from a Large, Randomized, Double-blind Trial // Anesthesiology. 2005. V. 103. P. 1225-32.

48. E. Soleyman-Zomalan, S. Motov, A. Likourezos, V. Cohen, I. Pushkar, C. Fromm. Patterns of Ketorolac dosing by emergency physicians // World J Emerg Med. 2017. V. 8 (1). P. 43-46.

49. J.R. Fricke, D. Angelocci, K. Fox, D. McHugh, L. Bynum, J.P. Yee. Comparison of the efficacy and safety of ketorolac and meperidine in the relief of dental pain // J Clin Pharmacol. 1992. V. 32(4). P. 376-84.

50. Приказ Министерства здравоохранения РФ № 70н от 15 февраля 2013 г. «Об утверждении требований к комплектации лекарственными препаратами и медицинскими изделиями комплекта индивидуального медицинского гражданской защиты для оказания первичной медико-санитарной помощи и первой помощи». URL: http://www.mchs.gov.ru/document/446399 (дата обращения 14.12.2017).

51. Abuse-Deterrent Opioids - Evaluation and Labeling. Guidance for Industry / Food and Drug Administration. Center for Drug Evaluation and Research (CDER). 2015. 26 p.

52. Н.Г. Венгерович, М.А. Юдин, А.С. Никифоров, Г.С. Сагалов, Э.А. Рузанова, Н.В. Шперлинг, А.И. Венгеровский, И.А. Шперлинг, А.С. Макачеев. Влияние комбинации фентанила и дексмедетомидина на функции внешнего дыхания при острой кровопотере // Бюллетень сибирской медицины. 2017. V. 16(2). P. 96-104.

53. I.K. Khanna, S. Pillarisetti. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain // Journal of Pain Research. 2015. V. 8. P. 859-870.

54. C. Martin, A. De Baerdemaeker, J. Poelaert, A. Madder, R. Hoogenboom, S. Ballet. Controlled-release of opioids for improved pain management // Materials Today. V. 19, Number 9. 2016. P. 491-502.

55. D.A. Volpe, G.A. McMahon Tobin, R.D. Mellon, A.G. Katki, R.J. Parker, T. Colatsky, T.J. Kropp, S. Leigh Verbois. Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs // Regulatory Toxicology and Pharmacology. 2011. V. 59. P. 385-390.

56. B. Zhang, T. Zhang, A.W. Sromek, T. Scrimale, J.M. Bidlack, J.L. Neumeyer. Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors // Bioorg Med Chem. 2011. V. 19(9). P. 2808-2816.

57. L.E. Mather. Opioids: a pharmacologist’s delight // Clin Exp Pharmacol Physiol. 1995. V. 22. P. 833-836.

58. F. Medzihradsky, P.J. Emmerson, C.A. Mousigian. Lipophilicity of Opioids Determined by a Novel Micromethod // JPM. 1992. V. 27 (2). P. 67-69.

59. DrugBank database. URL: https://www.drugbank.ca/drugs (дата обращения 24.12.2017).

60. Small Animal Toxicology / Ed. by M.E. Peterson, P.A. Talcott. - 2006. 1190 p.

61. J.W. Mandema, D.R. Stanski. Population pharmacodynamic model for ketorolac analgesia // Clin Pharmacol Ther. 1996. V. 60(6). P. 619-35.

62. Critical review of Ketamine 34th ECDD 2006/4.3. URL: https://www.drugbank.ca/unearth/q?utf8=%E2%9C%93&searcher=drugs&query=mu-Opioid+Receptor+Agonists (дата обращения 26.12.2017).

63. E. Bostro, M. Hammarlund-Udenaes, U.S.H. Simonsson. Blood-Brain Barrier Transport Helps to Explain Discrepancies in In Vivo Potency between Oxycodone and Morphine // Anesthesiology. 2008. V. 108. P. 495-505.

64. J.K. Coller, L.L. Christrup, A.A. Somogyi. Role of active metabolites in the use of opioids // Eur J Clin Pharmacol. 2009. V. 65(2). P. 121-39.

65. J. Cory Kalvass, E.R. Olson, M.P. Cassidy, D.E. Selley, G.M. Pollack. Pharmacokinetics and Pharmacodynamics of Seven Opioids in P-Glycoprotein-Competent Mice: Assessment of Unbound Brain EC50, and Correlation of in Vitro, Preclinical, and Clinical Data // The journal of pharmacology and experimental therapeutics. 2007. V. 323(1). P. 346-355.

66. P.P. Palmer. Efficacy and Safety of Sublingual Sufentanil 30 mcg for the Management of Acute Pain Following Ambulatory Surgery. AcelRx Pharmaceuticals. 2016.

67. S. Belli, F. Assmus, B. Wagner, M. Honer, H. Fischer, F. Schuler, R. Alvarez-Sánchez. Estimation of Drug Binding to Brain Tissue: Methodology and in Vivo Application of a Distribution Assay in Brain Polar Lipids // Mol. Pharmaceutics. 2015. V. 12(12). P. 4529-4541.

68. S. Beni, G. Toth, B. Noszal, S. Hosztafi. Preparation of benzoate esters of morphine and its derivatives // Monatsh Chem. 2012. V. 143(10). P. 1431-1440.

69. Patent US 2017143839. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof / T. Mickle, S. Guenther, G. Chi, J. Kanski, A.K. Martin, B. Bera. - 2017.

70. K. McWilliams, M. Fallon. Fast-acting fentanyl preparations and pain management // Q J Med. 2013. V. 106. P. 887-890.

71. Fentanyl Transdermal System (marketed as Duragesic) Information / FDA. URL: https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety-InformationforPatientsandProviders/ucm114961.htm (дата обращения 26.12.2017).

72. J.C. Scott, J.E. Cooke, D.R. Stanski. Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanil // Anesthesiol. 1991. V. 74. P. 34-42.

73. T.-J. Gan, P.P. Palmer, M.A. Royal. Sublingual Sufentanil, an “Ideal” Opioid for Acute and Breakthrough Pain: The Clinical Importance of CST½ and t½ke0. Poster presentation at the American Pain Society 2014 meeting. 2014. URL: http://www.acelrx.com/technology/publications/arx-04/2014%20APS%20Optimizing%20PK%20Poster%20Final%204%2022%2014.pdf (дата обращения 26.12.2017).

74. C. Metz, L. Gobel, M. Gruber, K.H. Hoerauf, K. Taeger. Pharmacokinetics of Human Cerebral Opioid Extraction. A Comparative Study on Sufentanil, Fentanyl, and Alfentanil in a Patient after Severe Head Injury // Anesthesiology. 2000. V. 92. P. 1559-67.

75. H.S. Minkowitz, D.Leiman, T. Melson, N. Singla, K.P. Di Donato, P.P. Palmer. Sufentanil Sublingual Tablet 30 mcg for the Management of Pain Following Abdominal Surgery: A Randomized, Placebo-Controlled, Phase-3 Study // Pain Practice. 2017. V. 17(7). P. 848-858.

76. M. Evashenk. Phase 3 Efficacy and Safety Results of the Sufentanil Sublingual Tablet 30 mcg (DSUVIA™). 2017. SOMSA Plenary Session.

77. H. Minkowitz, N. Singla, T. Melson, D. Leiman, K. Di Donato, P. Palmer. Safety and Efficacy of Sufentanil Sublingual 30mcg Tablets by Surgery Type for the Treatment of Acute Pain Following Outpatient Abdominal Surgery. 2016. SOMSA.

78. H.S. Minkowitz, N.K. Singla, M.A. Evashenk, S.S. Hwang, Yu-Kun Chiang, L.G. Hamel, P.P. Palmer. Pharmacokinetics of Sublingual Sufentanil Tablets and Efficacy and Safety in the Management of Postoperative Pain // Regional Anesthesia and Pain Medicine. 2013. V. 38 (2). P. 131-139.

79. Report of the International Narcotics Control Board on the Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes. UN. International Narcotics Control Board. 2010. URL: https://www.incb.org/documents/Publications/AnnualReports/AR2010/Supplement-AR10_availability_English.pdf (дата обращения 26.12.2017).

80. А.В. Соснов, С.С. Голубев, Б.С. Пунке вич, С.В. Садовников, Ф.М. Семченко, В.Н. Тохмахчи, А.А. Соснова. Оценка потребности Российской Федерации в сильнодействующих анальгетиках // Разработка и регистрация лекарственных средств. 2016. № 2(15). C. 202-215.

81. A.K. Chan, C. W. Cheung, Y.K. Chong. Alpha-2 agonists in acute pain management // Expert Opin Pharmacother. 2010. V. 11(17). P. 2849-68.

82. J.A. Giovannitti, S.M. Thoms, J.J. Crawford. Alpha-2 Adrenergic Receptor Agonists: A Review of Current Clinical Applications // Anesth Prog. 2015. V. 62(1). P. 31-38.

83. D.D. Price, D.J. Mayer, J. Mao, F.S. Caruso. NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance // J Pain Symptom Manage. 2000. V. 19(1). P. 7-11.

84. K. Subramaniam, B. Subramaniam, R. Steinbrook. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review // Anesth Analg. 2004. V. 99(2). P. 482-95.

85. D. Jamero, A. Borghol еt al. The Emerging Role of NMDA Antagonists in Pain Management // U.S. Pharmacist. 2001. V. 36(5). P. 4-8. URL: https://www.uspharmacist.com/article/the-emerging-role-of-nmda-antagonists-in-pain-management (дата обращения 02.12.2017).

86. C.S. Bonnet, A.S. Williams et al. AMPA/ kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis // Ann Rheum Dis. 2015. V. 74(1). P. 242-251.

87. D.R. Kirkpatrick et al. Transmission pathways and mediators as the basis for clinical pharmacology of pain // Expert Rev Clin Pharmacol. 2016. V. 4. P. 1-25.

88. A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam Nano-Tab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure // ClinicalTrials. AcelRx Pharmaceuticals, Inc. URL: https://clinicaltrials.gov/show/NCT00894699 (дата обращения 02.12.2017).

89. D. Perret, Z.D. Luo. Targeting voltagegated calcium channels for neuropathic pain management // Neurotherapeutics. 2009. V. 6(4). P. 679-92.

90. S. Goyal et al. Comparison of the Effects of Zonisamide, Ethosuximide and Pregabalin in the Chronic Constriction Injury Induced Neuropathic Pain in Rats // Ann Med Health Sci Res. 2015. V. 5(3). P. 189-96.

91. J.A. Fidler, Y.A. Jamal et al. GABA antagonist, delays return of righting reflex in mice after isoflurane anesthesia but does not significantly alter dendritic spine density // 46th Annu Meet Soc Neurosci. San Diego. 2016. Abst. 343.20.

92. P. Compton, P. Kehoe, K. Sinha. Gabaрentin improves cold-pressor pain res-ponses in methadone-maintained patients // Drug Alcohol Depend. 2010. V. 109(1-3). P. 213-9.

93. N. Stoicea, D. Russell, G. Weidner, M. Durda, S.D. Bergese. Opioid-induced hyperalgesia in chronic pain patients and the mitigating effects of gabapentin // Front Pharmacol. 2015. V. 27. P. 96-104.

94. D.L. Cichewicz. Synergistic interactions between cannabinoid and opioid analgesics // Life Sci. 2004. V. 74(11). P. 1317-1324.

95. J. Elikkottil, P. Gupta, K. Gupta. The analgesic potential of cannabinoids // J Opioid Manag. 2009. V. 5(6). P. 341-357.

96. L.R. Gerak, C.P. France. Combined Treatment with Morphine and Δ9- Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal // Journal of Pharmacology and Experimental Therapeutics. 2016. V. 357(2). P. 357-366.

97. D.R. Maguire, C.P. France. Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl // Eur J Pharmacol. 2016. V. 5(784). P. 199-206.

98. D.R. Maguire, C.P. France. Impact of efficacy at the μ-opioid receptor on antinociceptive effects of combinations of μ-opioid receptor agonists and cannabinoid receptor agonists // J Pharmacol Exp Ther. 2014. V. 351(2). P. 383-389.

99. F. Shen, P.R. Tsuruda, J.A. Smith, G.P. Obedencio, W.J. Martin. Relative contributions of norepinephrine and serotonin transporters to antinociceptive synergy between monoamine reuptake inhibitors and morphine in the rat formalin model // PLoS One. 2013. V. 8(9). P. 74891.

100. M.L. Banks, K.C. Rice, S.S. Negus. Antinociceptive interactions between Mu-opi-oid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of Mu agonist efficacy // J Pharmacol Exp Ther. 2010. V. 335(2). P. 497-505.

101. J.X. Li, W. Koek, K.C. Rice, C.P. France. Effects of direct- and indirect-acting serotonin receptor agonists on the antinociceptive and discriminative stimulus effects of morphine in rhesus monkeys // Neuropsychopharmacology. 2011. V. 36(5). P. 940-949.

102. K. Di Donato, P.P. Palmer, T.E. Morris, J. Walker, M. Casamayor, M. Hennebert. Intravenous administration of morphine in the emergency room inflicts a substantial economic burden in the EU5. Poster PSY45. ISPOR 19th Annual European Congress. 2016.

103. S.L. Kane-Gill. The cost of opioid-related adverse drug events // Journal of pain & palliative care pharmacotherapy. 2014. V. 28(3). P. 282-293.

104. H. Smith. A Comprehensive Review of Rapid-Onset Opioids for Breakthrough Pain // CNS Drugs. 2012. V. 26(6). P. 509-535.

105. N.M.L. Veldhorst-Janssen, A.A.A. Fiddelers, P.-H.M. van der Kuy, C. Neef, M.A.E. Marcus. A Review of the Clinical Pharmacokinetics of Opioids, Benzodiazepines, and Antimigraine Drugs Delivered Intranasally // Clinical Therapeutics. 2009. V. 31 (12). P. 2954-2987.

106. Oral ALLOD-2 vs. Its Components & vs. Placebo in the Acute Treatment of Migraine (ANODYNE-1). NCT03061734. 2017. URL: https://clinicaltrials.gov/show/NCT03061734 (дата обращения 10.12.2017).

107. L. Gorecki, J. Korabecny, K. Musilek, E. Nepovimova, D. Malinak, T. Kucera, R. Dolezal, D. Jun, O. Soukup, K. Kuca. Progress in acetylcholinesterase reactivators and in the treatment of organophosphorus intoxication: a patent review (2006-2016) // Expert Opinion on Therapeutic Patents. 2017. V. 27(9).

108. А.В. Соснов, М.И. Власов, С.В. Садовников, К.А. Руфанов, Ф.М. Семченко, А.А. Соснова, А.С. Радилов, Е.И. Савельева. Методы обнаружения токсикантов с использованием люминесцентных реагентов // Разработка и регистрация лекарственных средств. 2017. № 4(21). C. 108-125.

109. W.J. Geldenhuys, A.S. Mohammad, C.E. Adkins, P.R. Lockman. Molecular determinants of blood-brain barrier permeation // Ther. Deliv. 2015. V. 6(7). P. 961-971.

110. О.И. Рудько, Е.А. Климов, В.В. Соболев, А.В. Соснов, К.А. Руфанов, Ф.М. Семченко. Исследование влияния интраназального введения препарата дексмедетомидин на болевую чувствительность // Разработка и регистрация лекарственных средств. 2017. № 2 (19). C. 236-241.

111. V.N. Tohmahchi, M.S. Krymchak, A.I. Korovyakovskaya, F.M. Semchenko, A.V. Sosnov. Transdermal therapeutic systems for benzodiazepines // 250th American Chemical Society National Meeting. 2015. Poster.

112. И.Н. Станьков, В.Б. Кондратьев, И.Д. Деревягина, П.В. Казаков, О.И. Лукашов, О.Т. Морозова, Ф.М. Семченко, А.В. Соснов. Газохроматографическое определение микроколичеств эпибатидина и его биомаркера в плазме крови // Журнал аналитической химии. 2015. Т. 70. № 2. С. 189-195.

113. А.В. Соснов, С.С. Голубев, Б.С. Пункевич, С.В. Садовников, Е.М. Загребин, И.С. Родина, Ф.М. Семченко, А.А. Соснова. Стандартные образцы контролируемых сильнодействующих компонентов препаратов анальгетиков // Разработка и регистрация лекарственных средств. 2016. № 1(14). C. 216-223.

114. А.В. Соснов, Б.С. Пункевич, С.В. Садовников, Ф.М. Семченко. Разработка и выпуск стандартных образцов контролируемых биологически активных веществ ограниченного использования // II-я Международная научная конференция «Стандартные образцы в измерениях и технологиях». 2015.

115. Федеральный закон от 08.01.1998 № 3-ФЗ (ред. от 03.07.2016) «О наркотических средствах и психотропных веществах» (с изм. и доп., вступ. в силу с 01.01.2017). URL: http://www.consultant.ru/document/cons_doc_LAW_17437/ (дата обращения 02.12.2017).

116. Федеральный закон от 26.06.2008 № 102-ФЗ (ред. от 13.07.2015) «Об обеспечении единства измерений». URL: http://docs.cntd.ru/document/902107146 (дата обращения 14.12.2017).

117. Е.В. Осинцева. Тенденции и перспективы развития номенклатуры стандартных образцов в РФ // Материалы II-й Международной научной конференции «Стандартные образцы в измерениях и технологиях». 2015.